ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 1091 • ACR Convergence 2020

    A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD

    Sangmee Bae1, Andrea Oh2, Grace Kim3, Jonathan Goldin3 and Christina Charles-Schoeman4, 1University of California Los Angeles, Los Angeles, CA, 2National Jewish Health, Denver, CO, 3University of California, Los Angeles, Los Angeles, 4University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
  • Abstract Number: 1990 • ACR Convergence 2020

    Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

    Hanna Kim1, Lylan Bergeron2, Samantha Dill2, Michelle O'Brien2, Laura Vian3, Minal Jain4, Manuk Manukyan2, Xiaobai Li5, Shajia Lu3, Wanxia L. Tsai3, Kalyani Mishra Thakur6, Yinghui Shi6, Massimo Gadina7, April Brundidge2, Michelle Millwood2, Lisa G. Rider8 and Robert Colbert2, 1Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, 2Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 3Translational Immunology Section, NIAMS, NIH, Bethesda, MD, 4Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, 5Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, 6Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 7National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 8Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
  • Abstract Number: 0085 • ACR Convergence 2020

    Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition

    Fadi Charouf1, Netanel Karbian1, Itamar Altman1, Yakov Fellig1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
  • Abstract Number: 1070 • ACR Convergence 2020

    Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features

    Océane Landon-Cardinal1, Valérie Leclair2, Yves Troyanov3, Alain Meyer4, Sabrina Hoa1, Josiane Bourré-Tessier1, Valérie Nadon5, Julie Drouin6, Jason Karamchandani7, Erin O'Ferrall8, Minoru Satoh9, Marvin Fritzler10, Jean-Luc Senécal1, Marie Hudson2 and Benjamin Ellezam11, 1Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 3Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, 4Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, 5Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, 6Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, 7Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 8Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 9Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 10Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 11Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada

    Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
  • Abstract Number: 1092 • ACR Convergence 2020

    NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?

    Naveen R1, Anupam Guleria2, Dinesh Kumar2, Umesh Kumar2, Anamika Anuja1, Vikas Agarwal3 and Latika Gupta4, 1Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 2Centre of Biomedical Research, Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    Background/Purpose: Idiopathic inflammatory myositis (IIM) are rare and heterogenous. Myositis specific antibodies (MSA) show mutual exclusivity and identify specific clinical phenotypes1. Most biomarker studies are…
  • Abstract Number: 0451 • ACR Convergence 2020

    Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis

    Sophia Verspohl1, Tobias Holderried1, Charlotte Behning2, Peter Brossart1 and Valentin Schaefer3, 1Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
  • Abstract Number: 1073 • ACR Convergence 2020

    Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis

    Yuji Hosono1, Azusa Kojima2, Keigo Shimura2, Akira Ishii2, Yuto Izumi2, Kazuki Hirano2, Sho Sasaki2, Takayoshi Kurabayashi2, Noriko Sasaki2, Chiho Yamada2 and Shinji Sato2, 1Tokai University School of Medicine, Kanagawa, Japan, 2Tokai University School of Medicine, Isehara, Kanagawa, Japan

    Background/Purpose: Anti melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) positive dermatomyositis (DM) often complicates rapidly progressive interstitial lung disease (RP-ILD), which shows fatal prognosis at…
  • Abstract Number: 1093 • ACR Convergence 2020

    Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Hypertrophy in Sporadic Inclusion Body Myositis Patients

    Kasper Yde Jensen1, Henrik Daa Schrøder2, Jakob Nielsen3, Mikkel Jacobsen3, Eleanor Boyle3, Anders Nørkær Jørgensen3, Rune Dueholm Bech4, Per Aagaard3 and Louise Pyndt Diederichsen1, 1Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, 2Odense University Hospital, Odense, Denmark, 3University of Southern Denmark - Odense, Odense, Denmark, 4Zealand University Hospital, Copenhagen, Denmark

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is clinically characterised by marked progressive muscle weakness and impaired physical function. Physical training has become an area of…
  • Abstract Number: 0957 • ACR Convergence 2020

    Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis

    Bhargavi Duvvuri1, Lauren Pachman2, Richard Moore1, Stephen Doty3 and Christian Lood1, 1University of Washington, Seattle, WA, 2Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, 3The Hospital for Special Surgery, New York

    Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
  • Abstract Number: 1074 • ACR Convergence 2020

    A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine

    Karel Venne1, Valérie Leclair2, Julie D'Aoust1, Océane Landon-Cardinal3, Alexandra Albert4, Julie Beauchemin5, Denis Brunet6, Lucie Roy7, Benjamin Ellezam8, Jason Karamchandani9, Rami Massie10, Erin O'Ferrall10, Alain Meyer11, Yves Troyanov12, Minoru Satoh13, Marvin Fritzler14 and Marie Hudson2, 1Division of Rheumatology, Rheumatology Fellow, McGill University,, Montreal, QC, Canada, 2Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, 3Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 4Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, 5Division of Rheumatology, Hôpital Charles-Lemoyne, Longueuil, QC, Canada, 6Division of Neurology, Centre Hospitalier de l’Université Laval, Quebec, QC, Canada, 7Division of Rheumatology, CIUSSS du Saguenay Lac-Saint-Jean, Saguenay, Canada, 8Division of Pathology, CHU Sainte-Justine, Montreal, QC, Canada, 9Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 10Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 11Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 12Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, 13Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 14Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc). There is a paucity of data on scleromyositis…
  • Abstract Number: 1095 • ACR Convergence 2020

    Avascular Necrosis in the Hopkins Myositis Cohort: A Single Center Experience

    Khalil Bourji1, Christopher Mecoli2, Julie Paik3, Jemima Albayda3, Eleni Tiniakou3, William Kelly3, Thomas E Lloyd3, Andrew Mammen4 and Lisa Christopher-Stine3, 1Wayne State University/Henry Ford Hospital, Dearborn, MI, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4NIH, Bethesda, MD

    Background/Purpose: To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated…
  • Abstract Number: 0959 • ACR Convergence 2020

    Altered Gut Microbiome in Dermatomyositis

    Sangmee Bae1, Tien Dong2, Venu Lagishetty3, William Katzka4, Jonathan Jacobs3 and Christina Charles-Schoeman5, 1University of California Los Angeles, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, 3University of California, Los Angeles, Los Angeles, 4UCLA, Los Angeles, 5University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy associated with marked microvascular dysfunction and high morbidity and mortality. The gut microbiome has been implicated in the…
  • Abstract Number: 1075 • ACR Convergence 2020

    Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study

    Sandeepkumar Gupta1, Debendra Pattanaik2, Tulio Bertorini2 and Amado Afreire3, 1Medical College Of Georgia at Augusta University Medical Center, Augusta, GA, 2University of Tennessee Health Science Center, Memphis, TN, 3University of Tennessee Health Science Cente, Memphis, TN

    Background/Purpose: Myositis specific and associated autoantibodies are now being used more frequently in the diagnosis of idiopathic inflammatory myositis. However there is a no study…
  • Abstract Number: 1096 • ACR Convergence 2020

    Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis

    Jammie Law1, Ana Valle2, Katherine Mullins3 and Shereen Mahmood4, 1Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, New York, NY, 3Montefiore Medical Center, BROOKLYN, NY, 4Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY

    Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…
  • Abstract Number: 1055 • ACR Convergence 2020

    Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression

    Erin Wilfong1, Gabriel Schroeder1, April Barnado1, Steven Lord1, Narender Annapureddy1, Rosemarie Dudenhofer1 and Leslie J. Crofford1, 1Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Classification criteria for interstitial pneumonia with autoimmune features (IPAF) were introduced in 2015 to identify interstitial lung disease (ILD) patients who might benefit from…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology